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a) Background information 
 African Swine fever virus (ASFV) is the causative agent of African swine fever (ASF). ASFV is a devastating 
pathogen with a mortality rate of up to 100% in infected pig herds. It is prevalent and enzootic in 26 Sub-Saharan 
Africa (SSA) countries, reported in the years 2009-2011 (Penrith et al., 2013). Recently, outbreaks occurred in 
the Russian Federation resulting in economic losses estimated to be around 1 billion USD (FAO report, 2013) and 
the virus has now been reported in several other Eastern European countries, Asia and the American. This 
highlights the urgency of developing efficient countermeasures against ASF. There is no treatment nor 
commercial vaccine against ASF and the control of ASF is based on disease diagnostics, slaughter, and disposal 
of carcasses. Pigs are among the most profitable livestock for poor farmers. They are recognized as a species 
that can be used to improve livelihoods and contribute significantly to food security (Costard et al., 2009). With 
an estimated 34 million pigs in SSA, the development of an ASF vaccine could benefit about 6 to 17 million small-
holder farmers, in this region alone. In addition, pig farming in SSA involves many women, since cultural norms 
regard this as a job for women and young people. Thus, tackling this disease through the development of a 
vaccine will have the added effect of improving the lives of SSA women. 
Pigs that recover from infection are resistant to challenge against some ASFV isolates, indicating that these 
animals can develop a protective immune response (Lacasta et al., 2015). However, the complexity of ASFV, a 
virus encoding more than 150 different polypeptides (161 for “Kenya-1033” strain), many of them with 
unknown functions and others specialized in evading the immune system (Dixon et al., 2004), together with 
the variability of the virus isolates so far identified has complicated the identification of the mechanisms of 
protection against ASFV.  However, seminal evidence has demonstrated the key role humoral responses (Onisk 
et al., 1994 and Schlafer et al., 1984) and CD8+ T-cells (Oura et al., 2005 and Lacasta et al., 2015) can play in 
protection. Thus, passive transfer of sera or colostrum from ASFV-infected and recovered pigs partially 
protected pigs against homologous ASFV challenge (Onisk et al., 1994 and Schlafer et al., 1984).  
 
Three viral proteins were identified to be targets for neutralizing antibodies, p72/B646Lp, p54/E183Lp and 
p30/CP204Lp. Antibodies against p72 and p54 inhibit virus binding to cells, whereas those against p30 inhibit 
virus internalization. Other virion proteins present on the surface of intracellular mature or extracellular 
enveloped virus particles may be targets for neutralization by preventing virus entry or spread. These include 
the CD2v/EP402Rp, p12/O61Rp and D117Lp. However, there is a persistent 10% of the virus that is not 
neutralized in the in vitro assays. Hence, it is not surprising that protection outcome using combinations of the 
mentioned antigens move from no protection to partial protection, either using Baculovirus expressed 
proteins or DNA vaccination (reviewed in Arias et al., 2017 and Escribano et al., 2012).  
 
More recently, a virus expression library based on the avirulent ASFV strain Ba71V was used to screen the 
antibody specificity of polyclonal antisera from a surviving domestic pig infected with a virulent ASFV strain. 
Fourteen serological immunodeterminants were identified (Kollnberger et al., 2002). Unfortunately, no 
protection experiments followed these results.  
 
Our approach in this project is the generation of a complete plasmid DNA library with all ORFs from “Kenya 
1033” strain represented individually. The de novo synthesis of the genes and further cloning under the control 
of the CMV promoter will assure the accuracy of the gene sequences. GeneMill (University of Liverpool) is a 
leading expert in DNA design and cloning strategies. In the past, the construction of a library like the proposed 
was an important drawback because the difficulty of amplifying 161 ORF and cloning into individual plasmids. 
In most cases, the alternative was the construction of random libraries (Kollnberger et al., 2002 and Lacasta et 
al., 2014), with their intrinsic limitations. Using the automated DNA assembly technology in GeneMill allows 
the fast and efficient cloning of all 161 ASFV ORFs. 
 
The ASFV DNA library will be a very valuable resource for antigen screening. After transfecting the plasmids 
into mammalian cells these ones will be screened against polyclonal sera from the natural reservoir of ASFV, 
warthogs (Phacochoerus africanus) and also from domestic pigs (African and European breeds) surviving the 




collection of serum samples available and the collaboration with IRTA-CReSA will increase even more this 
collection. Furthermore, the DNA library will be designed to facilitate its use as a DNA immunogen. Hence, in 
future the identified antigens will be used single or in plasmid pools in immunogenicity studies and eventually 
challenge experiments. The project presented is a comprehensive approach that considers the initial research 
steps identifying protective antigens and future steps of animal immunization with a very versatile tool such as 
a plasmid DNA library. 
 
b) Objectives 
The objective of this project is to identify new ASFV antigens that target the antibody neutralizing activity. 
More specifically, we will screen a DNA library encoding all ORFs from ASFV “Kenya 1033” to find serological 
immunodeterminants with potential protective capacity against ASF.  
 
 
c) Experimental methodology 
 
1) Generation of a complete ASFV ORF plasmid DNA library and validation of the sequences. 
 
Proposed: All 161 ORFs from the virulent ASFV isolate Kenya 1033 (sequence available at ILRI) will be de novo 
synthetize by GeneMill (University of Liverpool). Hence, assuring the accuracy of the gene sequence. All ORFs 
will be cloned under the control of a cytomegalovirus (CMV) promoter. An extra plasmid will be generated 
with the sequence of the Green Fluorescent Protein (GFP) to be used as a general control for our assays. The 
generated plasmids will be expanded in bacteria, purified and sequenced. The final DNA library will be shipped 
to ILRI.  
 
Current status: GeneMill provided the complete library in April 2021. The library was validated at the ILRI labs 
isolating the individual DNA plasmids from bacteria and digesting using BamHI restriction enzyme. The 
quantity and the quality of the DNA plasmids was satisfactory, and the DNA plasmid library is ready to be used 
and stored at the ILRI Biorepository and inventoried in LabCollector LIMS software. A bacteria glycerol stock 
was also generated for every individual plasmid and it has been stored at the ILRI Biorepository facilities and 
inventoried in LabCollector LIMS software. 
 
2) Transfection of HEK293 cells with the plasmid collection. 
 
Proposed:  The ASFV DNA plasmid library will be assess for expression by transfecting the plasmids encoding 
GFP and the viral p72/B646Lp, p54/E183Lp and p30/CP204Lp proteins into HEK293 cells (transfection rates up 
to 90%). Expression of GFP protein and the efficiency of DNA transfection into HEK293 cells will be analysed by 
fluorescent microscopy and Flow Cytometry. Expression of p72, p54 and p30 will be assessed by Western Blot 
using the available anti-His and anti-Flag antibodies (every ORF is surrounded by a 6xHis and a Flag sequence 
at 5’ and 3’, respectively).  
After the initial validation of expression and localization of the library-encoded proteins the rest of plasmids 
will be transfected into HEK293 cells, generating a collection of cells expressing all ASFV Kenya 1033 proteins in 
individual clones (HEK293ASFVLib).  
 
Current status: GFP-ASFV DNA plasmid was used to assess the efficiency of transfection. The transfection 
efficiency ranged 70-80% of the cells fluorescent after 48h (Figure1). The expression of 6xHis and Flag was also 
assessed by means of Western Blot using commercially available anti-Flag and anti-His antibodies. The 
expression of GFP and also the Tags (His and Flag) was satisfactory. A set of 4 plasmids encoding the ASFV 
proteins: p30, p54, p72 and CD2v were assessed after transfection to HEK293 with the optimized protocol. P30 







Figure 1. HEK293 cells transfected with a DNA plasmid encoding Green Fluorescent Protein (GFP). Cells in 
green are positive for transfection and protein expression.  
 
 
3) Sera collection from warthogs (Phacochoerus africanus).  
 
Proposed: Comparison of the pattern of antigen recognition between domestic ASFV susceptible pigs and 
resistant wild reservoirs (bushpigs and warthogs) will be of great interest.  We will collect sera from wild 
animals in ASF positive areas in Kenya in collaboration with the Kenyan Wildlife Service (KWS). ILRI already has 
a big collection of sera samples from domestic animals positive for anti-ASFV antibodies from naturally 
infected animals and from experimental animals. Moreover, IRTA-CReSA will send to ILRI sera samples from 
recovered experimental domestic pigs infected with different ASFV isolates from different genotypes. We will 
also have access to the Friederich Loweffler institute (FLI) serum samples, they are current close collaborators 
with ILRI. Thus, there is no need to sample domestic animals for this project.  
 
Current status: A set of around 200 samples from domestic animals have been identified. The animals were 
exposed to infection with ASFV attenuated virus, ASFV inactivated virus and ASFV subunit vaccination. A 
collection of 32 samples from warthogs were also identified form the ILRI Biorepository facilities and they are 
available for analysis. All samples were analysed to detect ASFV antibodies under both ELISA and 
Immunoperoxidase Monolayer Assay (IPMA). The positive samples were selected for further analysis. The 
relevant permits for wild animal sampling in collaboration with the KWS are in the process of obtention. 
However, the analysis of the already available samples will go ahead.  
 
4) Antibody reactivity to HEK293ASFVLib individual clones. 
 
Proposed: In a first round of screening, sera from domestic African and European pigs recovered from either 
virulent or attenuated infection and sera from warthog will be screened against the HEK293ASFVLib by means of 
IPMA. If necessary, a panning step to remove antibodies against p72, p30 and p54 proteins (immunodominant 
antigens already identified) and the concentration of the remaining antibodies will be performed. Sera 
detecting new antigens will be selected for further analysis.  
 
Current status: The use of IPMA as read-out for the screening has been validated and the protocol is ready to 
be used routinely. The strategy for screening will comprise the generation of pools of DNA plasmids (including 
GFP in all pools to assess transfection efficiency). The efficiency of this strategy has already been validated.  
 
5) ASFV neutralization assay and cross-reaction.  
 
Proposed: The selected sera samples will be tested for their capacity to neutralize ASFV in vitro. In order to test 




against other virulent and attenuated ASFV strains from different genotypes from our ILRI and IRTA-CReSA 
collection. A combination of sera recognizing different antigens will be also tested under the virus 
neutralization assay. Technology transfer will be provided in order to standardize the neutralization assay 
protocols between the two laboratories. We do not discard to expand the number of neutralization assays to 
assess additional antibody mechanisms of protection such as complement mediated cell lysis or antibody-
dependant cell-mediated cytotoxicity (ADCC), potentially involved in protection against ASFV (reviewed in 
Escribano et al., 2012).  Antigen-specific antibodies from the successful sera samples will be purified and 
concentrated and used in a neutralization assay single or in combination with other antigen-specific 
antibodies. The antigen-specific antibody purification is a standardized protocol at ILRI that has been used 
successfully for research on other diseases (e.g. East Coast fever). Successful antigens will be selected for 
future in vivo immunogenicity studies.  
 
Current status: an ASFV seroneutralization assay has been developed and controlled rabbit antisera against 
inactivated ASFV, p30 and p54 are being used as positive and negative controls for neutralization (Figure 2). 
The rabbit sera were produced from a CGIAR Research Program project to be used across all ILRI ASFV 
projects. The ILRI seroneutralization assay is using an ASFV strain with GFP cloned in its genome. The ASFV-GFP 
virus is fluorescent allowing to use FACS analysis as a read-out for this assay, making it semi-quantitative and 
not only qualitative. All the ELISA and IPMA positive serum samples are in the process of being tested. IRTA-













































































BUDGET STATUS REPORT (at 8 December 2021) 
 
Donor: International Veterinary Vaccinology Network (IVVN) 
Project Period: February 2019 to  April 2022 
Reporting Period: September 2019-November 2021 
Reporting Currency:  GBP 
Project Budget: GBP 94,692 
Project OH Rate: 17% 
   
General Comments  
Funds Received to date from Donor GBP 85,221 
Expenditure to date GBP 68,672 
Commitments to date GBP 12 
Budget Balance to date exclusive of 
commitments GBP 26,020 
Budget Balance to date inclusive of 
commitments GBP 26,008 
Cofinancing total to date N/A 
Payment to Partner to date GBP 35,077 
Amount Available for Supplies GBP 8,550 
Amount Available for Travel GBP 2,526 
Linear Budget Projection Burn rate at 
close of period 92% 
Linear Actual Project Burn rate at close 
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